Global Kidney Cancer and Renal Cell Carcinoma Drugs Market - 2023-2030
The Global Kidney Cancer and Renal Cell Carcinoma Drugs Market reached US$ 5.6 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 8.9 billion by 2030. The global kidney cancer and renal cell carcinoma drugs market is expected to exhibit a CAGR of 6.3% during the forecast period (2023-2030).
The development of novel medications and kidney cancer treatment strategies is receiving significant funding from pharmaceutical corporations and research organizations. The introduction of additional cutting-edge and potent medications to the market is anticipated to result from this ongoing research and development activity, spurring future expansion.
Market Dynamics
Active Major Players Are Boosting The Global Kidney Cancer And Renal Cell Carcinoma Drugs Market Growth During The Forecast Period.
In October 2022, on the approach to receiving FDA approval for its kidney cancer medication Fotivda, Aveo Oncology took a diversion. LG Chem now intends to have better success developing Fotivda and Aveo's other cancer candidates due to Aveo's acquisition of LG Chem. Aveo has three other cancer candidates in addition to Fotivda, which was unexpectedly approved by the FDA in March for the third-line treatment of advanced renal cell carcinoma that has relapsed or is resistant.
Aveo recently found that its patent on Fotivda, set to expire in 2028, could really be extended all the way to 2039, making it more desirable for LG Chem.
The Development Of Personalized Medicines Provides Kidney Cancer And Renal Cell Carcinoma Drug Market Growth Opportunities.
Personalized medicine techniques have been created as a result of our growing understanding of the genetic and molecular aspects of kidney cancer. In order to develop customized treatment plans, genetic testing, and biomarker analyses help detect certain mutations or abnormalities in tumors. Drugs that target particular genetic defects are in high demand due to the focus on personalized therapy, which is propelling market expansion.
Targeted medicines that specifically tackle particular molecular targets involved in kidney cancer and RCC have been made possible by personalized medicine. These medications, such as immune checkpoint inhibitors and tyrosine kinase inhibitors (TKIs), are made to block particular molecules or pathways that are essential for the development and survival of tumors.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the kidney cancer and renal cell carcinoma drugs market. The pandemic has impacted worldwide logistics and supply chains, which has caused disruptions in the accessibility of drugs, especially those required to treat kidney cancer and RCC. Despite efforts to keep a consistent supply of important pharmaceuticals, there have occasionally been shortages and delays in their delivery. Additionally, border closures and limits on transportation may have hindered the import and export of pharmaceuticals, which could have hampered access in some regions.
As of 2023, the COVID-19 situation is recovering and all patients can access the healthcare facilities leading to increasing demand for kidney cancer and renal cell carcinoma drugs.
Russia-Ukraine Conflict Analysis
The impact of the Russia-Ukraine war on the kidney cancer and renal cell carcinoma drugs market is complex and multifaceted. The dispute may put a strain on the healthcare system, taking resources and focus away from specialized treatments like cancer therapy. Providing the best care may present issues for hospitals and healthcare facilities, including access to specialized medications.
Segment Analysis
The global kidney cancer and renal cell carcinoma drugs market is segmented based on product, end-user, distribution channel, and region.
The Everolimus Segment Is Expected To Hold A Position In The Market Over The Forecast Period.
The Everolimus segment accounted for one of the highest market stake accounting for approximately 22.3% of the kidney cancer and renal cell carcinoma drugs market in 2022. Everolimus works by inhibiting the mTOR pathway, which is involved in regulating cell growth, proliferation, and angiogenesis (the formation of new blood vessels). By inhibiting mTOR, Everolimus helps slow down the growth of cancer cells and prevents the formation of new blood vessels that supply nutrients to the tumor. Everolimus can be used as a single agent or in combination with other drugs for the treatment of advanced RCC.
Geographical Analysis
An Increasing Number Of Patients With Kidney Cancer, FDA Approvals, And Advancement In Kidney Cancer And Renal Cell Carcinoma Drugs Dominate The European Region.
Europe is expected to dominate the kidney cancer and renal cell carcinoma drugs market, accounting for around 27.9% of this market. Different European nations have different rates of kidney cancer, particularly renal cell carcinoma (RCC). With more than 115,000 cases identified each year and 49,000 fatalities, kidney cancer is the fifth most prevalent malignancy in Europe.
In Europe, there are more people over the age of 65 than anywhere else in the world. The incidence of kidney cancer tends to rise with age, and the aging population adds to the disease's overall prevalence.
Competitive Landscape
The major global players in the market include Roche Inc, GlaxoSmithKline Plc., Active Biotech Ab., Heidelberg Pharma AG, Inc., Bristol-Myers Squibb, Eisai, Exelixis, Novartis AG, Amgen, and Bayer AG among others.
Why Purchase the Report?
• To visualize the global kidney cancer and renal cell carcinoma drugs market segmentation based on the product, end-users, distribution channel, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous kidney cancer and renal cell carcinoma drugs market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global kidney cancer and renal cell carcinoma drugs market report would provide approximately 61 tables, 63 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Product
- 3.2. Snippet by End-users
- 3.3. Snippet by Distribution Channel
- 3.4. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Growing incidences of kidney and RCC cases
- 4.1.2. Restraints
- 4.1.2.1. Side effects associated with These Drugs
- 4.1.3. Opportunity
- 4.1.3.1. Research and development
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers’ Strategic Initiatives
- 6.6. Conclusion
- 7. Russia-Ukraine War Analysis
- 8. Artificial Intelligence Analysis
- 9. By Product
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 9.1.2. Market Attractiveness Index, By Product
- 9.2. Bevacizumab*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Everolimus
- 9.4. Cabozantinib
- 9.5. Axitinib
- 9.6. Sorafenib
- 9.7. Temsirolimus
- 9.8. Sunitinib
- 9.9. Pazopanib
- 10. By End-users
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 10.1.2. Market Attractiveness Index, By End-users
- 10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Ambulatory Surgical Centers
- 10.4. Specialty Clinics
- 10.5. Others
- 11. By Distribution Channel
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.1.2. Market Attractiveness Index, By Distribution Channel
- 11.2. Hospital Pharmacies*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.3. Retail Pharmacies
- 11.4. Online Pharmacies
- 12. By Region
- 12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
- 12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.2.6.1. The U.S.
- 12.2.6.2. Canada
- 12.2.6.3. Mexico
- 12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.3.6.1. Germany
- 12.3.6.2. The U.K.
- 12.3.6.3. France
- 12.3.6.4. Italy
- 12.3.6.5. Spain
- 12.3.6.6. Rest of Europe
- 12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.4.6.1. Brazil
- 12.4.6.2. Argentina
- 12.4.6.3. Rest of South America
- 12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.5.6.1. China
- 12.5.6.2. India
- 12.5.6.3. Japan
- 12.5.6.4. Australia
- 12.5.6.5. Rest of Asia-Pacific
- 12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 13. Competitive Landscape
- 13.1. Competitive Scenario
- 13.2. Product Benchmarking
- 13.3. Company Share Analysis
- 13.4. Key Developments and Strategies
- 14. Company Profiles
- 14.1. Roche Inc*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
- 14.2. GlaxoSmithKline Plc.
- 14.3. Active Biotech Ab
- 14.4. Heidelberg Pharma AG, Inc.
- 14.5. Bristol-Myers Squibb
- 14.6. Eisai
- 14.7. Exelixis.,
- 14.8. Novartis AG
- 14.9. Amgen
- 14.10. Bayer AG
- LIST NOT EXHAUSTIVE
- 15. Appendix
- 15.1. About Us and Services
- 15.2. Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook